Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098345 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00098345 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 40 participants.
The verdict
NCT00098345, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
Interventions
- DRUG ZD6474 (vandetanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-11 |
| Est. Completion | 2017-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098345
The ClinicalTrials.gov registry entry for NCT00098345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZD6474 (vandetanib) is the first listed.
NCT00098345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098345 about?
NCT00098345 is a clinical study titled "Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer". The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
What is the current status of trial NCT00098345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-11. Estimated completion is 2017-04-19.
What interventions are being tested in trial NCT00098345?
The interventions under investigation include: ZD6474 (vandetanib) (DRUG).
Who is sponsoring clinical trial NCT00098345?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.